As a result of the search for better risk stratification in AML patients with normal cytogenetics, high diagnostic expression of the AML-associated genes BAALC and MN1 were shown to have independent adverse prognostic impact on CR achievement, relapse rates, EFS, and OS in younger [4, 9, 12–14, 27–29] and older [10–12] AML patients. The gene discussed is BAALC; the disease is acute myeloid leukemia.